The Drugs Controller General of India has sought clarification from Glenmark for alleged false claims that its favipiravir-based COVID-19 drug FabiFlu is effective on patients with co-morbid conditions like hypertension and diabetes. DCGI also said the total cost of treatment with FabiFlu is ₹12,500, which is "definitely not in the interest of the poor, lower middle class and middle-class people".